Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 37 citing articles:

Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2
Yufei Xiang, Sham Nambulli, Zhengyun Xiao, et al.
Science (2020) Vol. 370, Iss. 6523, pp. 1479-1484
Open Access | Times Cited: 402
Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses
Sham Nambulli, Yufei Xiang, Natasha L. Tilston‐Lunel, et al.
Science Advances (2021) Vol. 7, Iss. 22
Open Access | Times Cited: 140
A comprehensive comparison between camelid nanobodies and single chain variable fragments
Yasaman Asaadi, Fatemeh Fazlollahi Jouneghani, Sara Janani, et al.
Biomarker Research (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 119
Pulmonary Delivery of Biological Drugs
Wanling Liang, Harry W. Pan, Driton Vllasaliu, et al.
Pharmaceutics (2020) Vol. 12, Iss. 11, pp. 1025-1025
Open Access | Times Cited: 129
Viral Emerging Diseases: Challenges in Developing Vaccination Strategies
Maria Trovato, Rossella Sartorius, Luciana D’Apice, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 119
An update of anti-viral treatment of COVID-19
Serap Şimşek Yavuz, İpek Komşuoğlu Çelikyurt
TURKISH JOURNAL OF MEDICAL SCIENCES (2021) Vol. 51, Iss. SI-1, pp. 3372-3390
Open Access | Times Cited: 78
The find of COVID-19 vaccine: Challenges and opportunities
Marwan ElBagoury, Mahmoud M. Tolba, Hebatallah A. Nasser, et al.
Journal of Infection and Public Health (2020) Vol. 14, Iss. 3, pp. 389-416
Open Access | Times Cited: 63
Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody
G Valenzuela, Ronald Jara, Daniel Watterson, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 46
Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics
Lennox Chitsike, Penelope J. Duerksen-Hughes
Virology Journal (2021) Vol. 18, Iss. 1
Open Access | Times Cited: 41
Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era
Simone Pecetta, Oretta Finco, Anja Seubert
Seminars in Immunology (2020) Vol. 50, pp. 101427-101427
Open Access | Times Cited: 44
Nano-engineered tools in the diagnosis, therapeutics, prevention, and mitigation of SARS-CoV-2
Siya Kamat, Madhuree Kumari, Chelliah Jayabaskaran
Journal of Controlled Release (2021) Vol. 338, pp. 813-836
Open Access | Times Cited: 38
Prospects of Neutralizing Nanobodies Against SARS-CoV-2
Fangfang Chen, Zhihong Liu, Fan Jiang
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 36
Can Immunization of Hens Provide Oral-Based Therapeutics against COVID-19?
José Manuel Pérez de la Lastra, Victoria Baca-González, Patricia Asensio-Calavia, et al.
Vaccines (2020) Vol. 8, Iss. 3, pp. 486-486
Open Access | Times Cited: 31
Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases
Tharmala Tharmalingam, Xiaobing Han, Ashley Wozniak, et al.
Human Vaccines & Immunotherapeutics (2021) Vol. 18, Iss. 2
Open Access | Times Cited: 23
Versatile, Multivalent Nanobody Cocktails Efficiently Neutralize SARS-CoV-2
Yufei Xiang, Sham Nambulli, Zhengyun Xiao, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 24
Can CRISPR/Cas Technology Be a Felicitous Stratagem Against the COVID-19 Fiasco? Prospects and Hitches
Rocktotpal Konwarh
Frontiers in Molecular Biosciences (2020) Vol. 7
Open Access | Times Cited: 18
Transforming nanobodies into high-precision tools for protein function analysis
Jan Gettemans, Brian De Dobbelaer
AJP Cell Physiology (2020) Vol. 320, Iss. 2, pp. C195-C215
Open Access | Times Cited: 18
Nanobodies as powerful pulmonary targeted biotherapeutics against SARS-CoV-2, pharmaceutical point of view
Ali Najmeddin, Mina Bahrololoumi Shapourabadi, Mahdi Behdani, et al.
Biochimica et Biophysica Acta (BBA) - General Subjects (2021) Vol. 1865, Iss. 11, pp. 129974-129974
Open Access | Times Cited: 15
The Perspective on Bio-Nano Interface Technology for Covid-19
Sathish‐Kumar Kamaraj
Frontiers in Nanotechnology (2020) Vol. 2
Open Access | Times Cited: 14
Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses
Sham Nambulli, Yufei Xiang, Natasha L. Tilston‐Lunel, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 13
Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2
Phillip Pymm, Samuel J. Redmond, Olan Dolezal, et al.
iScience (2022) Vol. 25, Iss. 11, pp. 105259-105259
Open Access | Times Cited: 9
A Naïve Phage Display Library-Derived Nanobody Neutralizes SARS-CoV-2 and Three Variants of Concern
Dandan Wu, Junxiao Cong, Jiali Wei, et al.
International Journal of Nanomedicine (2023) Vol. Volume 18, pp. 5781-5795
Open Access | Times Cited: 4
Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity Nanobody
G Valenzuela, Ronald Jara, Daniel Watterson, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Closed Access | Times Cited: 12
Fast isolation of sub-nanomolar affinity alpaca nanobody against the Spike RBD of SARS-CoV-2 by combining bacterial display and a simple single-step density gradient selection
Guillermo E. Valenzuela Nieto, Ronald Jara, Daniel Watterson, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 10
FN3-based monobodies selective for the receptor binding domain of the SARS-CoV-2 spike protein
Christina Miller, Jennifer E. McGinnis, Michael J. Martinez, et al.
New Biotechnology (2021) Vol. 62, pp. 79-85
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top